• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Genmab A/S

< Previous 1 2 3 4 Next >
News headline image
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
May 21, 2026
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Major Shareholder Announcement
May 08, 2026
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Financial Results for the First Quarter of 2026
May 07, 2026
From Genmab A/S
Via GlobeNewswire
News headline image
Major Shareholder Announcement
April 14, 2026
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
April 14, 2026
From Genmab A/S
Via GlobeNewswire
News headline image
Major Shareholder Announcement
April 01, 2026
From Genmab A/S
Via GlobeNewswire
News headline image
Major Shareholder Announcement
March 30, 2026
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Publishes 2025 Annual Report
February 17, 2026
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
April 13, 2026
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
January 21, 2026
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
January 16, 2026
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
January 16, 2026
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
January 07, 2026
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Portfolio Prioritization Update
December 29, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Portfolio Prioritization Update
December 29, 2025
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
December 12, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB MRUS
News headline image
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
December 12, 2025
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
December 08, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
December 06, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
December 07, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
November 19, 2025
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
November 18, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
November 18, 2025
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Financial Results for the Nine Months of 2025
November 06, 2025
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
November 03, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
October 14, 2025
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
September 29, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB MRUS
News headline image
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
September 29, 2025
From Genmab A/S
Via GlobeNewswire
News headline image
Major Shareholder Announcement
September 23, 2025
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
September 03, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap